甲状腺癌中p33ING1、ER、PR和c-erbB-2的表达及意义

目的:探讨抑癌基因p33ING1、雌激素受体(ER)、孕酮受体(PR)和癌基因c-erbB-2蛋白在甲状腺癌组织中的表达.方法:应用免疫组化SP法检测甲状腺腺瘤(TA)和腺癌(TC)中p33ING1、ER、PR和c-erbB-2的表达,分析其与肿瘤临床病理特征之间的关系.结果:p33ING1、ER、PR和c-erbB-2的阳性表达率在40例腺瘤中分别为76.5%、35.0%、40.0%和5.0%;在45例腺癌中分别为41.2%、57.8%、64.4%和46.7%,组间比较差异均有统计学意义(P＜0.05或P＜0.01).p33ING1、ER、PR与c-erbB-2呈负相关(r分别为-0.218、-0.221、-0.213,均P＜0.05).结论:p33ING1、ER、PR和c-erbB-2蛋白可能共同参与甲状腺癌的发生发展,是预测甲状腺癌预后的有效指标.

Expressions of p33ING1, ER, PR and c-erbB-2 in Thyroid Carcinomas

Objective: To study the expressions of p33ING1, estrogen receptor(ER),progestrone receptor(PR) and c-erbB-2 in the specimens of thyroid carcinomas. Methods:The immunohistochemical methods(SP) were used to detect the expressions ofp33ING1',ER,PR and c-erbB-2 in specimens of thyroid adenomas (TA) and thyroid carcinomas (TC). Results:The positive expression rates of p33ING1, ER, PR and c-erbB-2 protein were76.5%,35.0%,40.0% and 5.0% in TA; and 41.2%,57.8%,64.4%and 46.7% in TC, respectively. There was a significant difference between groups (P＜0.05 or P＜0.01). There was a negative correlation between expressions of e-erbB-2 protein and p33ING1, ER, PR(r=-0.218, -0.221, -0.213, P＜0.01). Conclusion:It may play an important role that p33ING1, ER, PR and e-erbB-2 protein in occurrence and development of thyroid carcinoma,and they may be factors to predict the prognosis of thyroid carcinoma.